litlas
Log inCreate account

Tudor–Eliade Ciuleanu

Active 2004–2026

Also published as
Tudor-Eliade Ciuleanu
109
Papers
37,956
Citations
69
h-index
102
i10-index

Citations

Citations per year for Tudor–Eliade Ciuleanu1971: 1 citations2001: 1 citations2002: 1 citations2004: 9 citations2005: 52 citations2006: 134 citations2007: 178 citations2008: 174 citations2009: 203 citations2010: 214 citations2011: 216 citations2012: 198 citations2013: 283 citations2014: 201 citations2015: 261 citations2016: 277 citations2017: 315 citations2018: 417 citations2019: 1,315 citations2020: 1,344 citations2021: 1,324 citations2022: 1,053 citations2023: 992 citations2024: 1,553 citations2025: 795 citations2026: 15 citations1972–2000: no citations, so these years are not shown2003: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,740 citing papers, 23.5% of this breakdownChina: 2,189 citing papers, 13.8% of this breakdownItaly: 928 citing papers, 5.8% of this breakdownUnited Kingdom: 767 citing papers, 4.8% of this breakdownFrance: 756 citing papers, 4.7% of this breakdownJapan: 743 citing papers, 4.7% of this breakdownSpain: 687 citing papers, 4.3% of this breakdownGermany: 686 citing papers, 4.3% of this breakdownCanada: 562 citing papers, 3.5% of this breakdownNetherlands: 390 citing papers, 2.5% of this breakdownSouth Korea: 380 citing papers, 2.4% of this breakdownSwitzerland: 377 citing papers, 2.4% of this breakdown
0%23.5%Other 23.3%

Institutions

Fields

  • Medicine80.4%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Immunology and Microbiology4.4%
  • Engineering0.5%
  • Materials Science0.4%
  • Mathematics0.3%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers14.7%
  • Lung Cancer Treatments and Mutations11.5%
  • Lung Cancer Research Studies6.7%
  • Lung Cancer Diagnosis and Treatment5%
  • Cancer Genomics and Diagnostics4%
  • Immunotherapy and Immune Responses3.9%
  • Other54.2%

Coauthors

All papers

Open in search
  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

    Authors: Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen R. Broderick, Julie R. Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Tudor-Eliade Ciuleanu, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Janis M. Taube, Cecile Dorange, Junliang Cai, Joseph Fiore, Anthony Jarkowski, David Balli, Mark Sausen, Dimple Pandya, Christophe Y. Calvet, Nicolas Girard - New England Journal of Medicine 2022 cited by 2,558

  2. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Authors: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Thomas John, David P. Carbone, S. Meadows–Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck - The Lancet Oncology 2021 cited by 1,362

  3. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Authors: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 cited by 3,137

  4. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    Authors: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 cited by 2,575

  5. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    Authors: Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, László Urbán, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Płużański, Jacobus A. Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam - Journal of Clinical Oncology 2022 cited by 381

  6. Perioperative Nivolumab in Resectable Lung Cancer

    Authors: Tina Cascone, Mark M. Awad, Jonathan Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor–Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Steven I. Blum, Mariano Provencio - New England Journal of Medicine 2024 cited by 447

  7. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Eugene D. Kwon, Charles G. Drake, H. I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, C. Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen - The Lancet Oncology 2014 cited by 1,496

  8. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Authors: Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol - The Lancet 2014 cited by 1,308

  9. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

    Authors: Robert L. Ferris, Robert I. Haddad, Caroline Even, Makoto Tahara, Mikhail Dvorkin, Tudor–Eliade Ciuleanu, Paul M. Clément, Ricard Mesı́a, С. И. Кутукова, Lyubov Zholudeva, Amaury Daste, Javier Caballero-Daroqui, Bhumsuk Keam, Ihor Vynnychenko, C. Lafond, Jagdish Shetty, Helen Mann, Jean Fan, Sophie Wildsmith, Nassim Morsli, Jérôme Fayette, Lisa Licitra - Annals of Oncology 2020 cited by 365

  10. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Authors: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 cited by 322

  11. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    Authors: Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah - The Lancet Oncology 2015 cited by 955

  12. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

    Authors: Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Felipe Reyes, P.-J. Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Luis Paz‐Ares, David P. Carbone, Arteid Memaj, S. Marimuthu, X. Zhang, Phuong Tran, Thomas John - ESMO Open 2021 cited by 188

  13. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

    Authors: David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu, Scott Gettinger, Solange Peters, Leora Horn, Clarisse Audigier-Valette, N. Pardo Aranda, Óscar Juan, Ying Cheng, H. Zhang, Meiqi Shi, Alexander Luft, Juergen Wolf, Scott Antonia, Kazuhiko Nakagawa, Justin Fairchild, Christine Baudelet, Devangini K. Pandya, Parul Doshi, Han Chang, Martin Reck - Annals of Oncology 2021 cited by 271

  14. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 cited by 5,451

  15. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    Authors: Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F. Smit, Alberto Chiappori, M.E. Olmedo, Ildikó Horváth, Christian Grohé, Anna F. Farago, José Antonio López-Vilariño, Martín Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromı́r Roubec, Konstantinos Syrigos, Gregory Lo, I. Barneto, Anthony Pope, Amparo Martínez Sánchez, Joseph Kattan, Paul Zarogoulidis, Cornelius F. Waller, Helge Bischoff, Óscar Juan, Niels Reinmuth, Manuel Dómine, Luis Paz‐Ares - The Lancet Respiratory Medicine 2022 cited by 120

  16. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    Authors: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü - Journal of Clinical Oncology 2024 cited by 135

  17. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Authors: Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor–Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd - The Lancet Oncology 2013 cited by 526

  18. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

    Authors: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Óscar Juan, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, J. Menezes, Jacek Jassem, Светлана Проценко, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Żurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker R. Dakhil, Shun Lü, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone - Journal of Thoracic Oncology 2022 cited by 97

  19. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

    Authors: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis - European Urology 2020 cited by 175

  20. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

    Authors: Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, Tudor–Eliade Ciuleanu, Caio Guilherme Pereira, Eva Muñoz‐Couselo, Fernanda Damian, Michael Schenker, Aldo Perfetti, Célèste Lebbé, G. Quéreux, Friedegund Meier, Brendan D. Curti, Carlos A. Rojas, Yull Arriaga, Hai-Su Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary Tagliaferri, Nikhil I. Khushalani - Journal of Clinical Oncology 2023 cited by 72

  21. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

    Authors: M. M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, Olena Kolesnik, В. В. Іванченко, Alexander S. Dudnichenko, Birutė Aleknavičienė, Artūras Razbadauskas, Martin Gore, Elena Ganea‐Motan, Tudor–Eliade Ciuleanu, Pauline Wimberger, Alexander Schmittel, Barbara Schmalfeldt, Alexander Burges, Carsten Bokemeyer, Horst Lindhofer, Angelika Lahr, Simon L. Parsons - International Journal of Cancer 2010 cited by 551

  22. Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    Authors: Mary O’Brien, Tudor–Eliade Ciuleanu, H. Tsekov, Yaroslav Shparyk, Branka Čučeviá, Gábor Juhász, Nicholas Thatcher, Graham Ross, G. Dane, T. Crofts - Journal of Clinical Oncology 2006 cited by 639

  23. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    Authors: Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman, Enriqueta Felip, Tudor–Eliade Ciuleanu, M.R. García Campelo, Kevin Jao, Fabrice Barlési, Stéphanie Bordenave-Juchereau, Erika Rijavec, László Urbán, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Arén Frontera, Alessandra Curioni‐Fontecedro, Amparo Sánchez-Gastaldo, Óscar Juan, Helena Linardou, Elena Poddubskaya, David R. Spigel, Samreen Ahmed, Michele Maio, Sunney Li, Han Chang, Joseph Fiore, A. Acevedo, Luis Paz‐Ares - Journal for ImmunoTherapy of Cancer 2023 cited by 73

  24. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    Authors: Martin Reck, Tudor–Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Żurawski, Sang‐We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Płużański, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martínez‐Martí, Koichi Azuma, Rita Axelrod, Luis Paz‐Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O’Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer - Journal of Thoracic Oncology 2023 cited by 72